Metoprolol Alvogen

Metoprolol Tartrate, the active ingredient in Metoprolol Alvogen, is a beta blocker presented as an oral tablet for oral use. It lowers blood pressure and heart rate, and is used to manage hypertension, angina pectoris, heart failure, and post‑myocardial infarction in adult patients.

GNH USA supplies Metoprolol Alvogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, ensuring timely delivery and regulatory compliance.

Metoprolol Alvogen, a selective β1‑adrenergic blocker, is employed in cardiovascular conditions where reduction of cardiac workload is desired.

- Hypertension: reduces systolic and diastolic pressure, decreasing risk of stroke and organ damage. - Angina pectoris: lowers myocardial oxygen demand, relieving chest‑pain episodes. - Heart failure: improves ventricular function and reduces hospitalization rates. - Post‑myocardial infarction: decreases mortality and recurrent ischemic events.

Metoprolol Alvogen may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue - Dizziness - Cold extremities - Bradycardia - Gastrointestinal upset - Sleep disturbances

Serious or Rare Side Effects: - Severe bradycardia - Heart block - Marked hypotension - Bronchospasm in asthmatic patients - Depression - Allergic reactions such as rash or angioedema

When prescribing Metoprolol Alvogen, clinicians should consider several safety measures. - Monitor blood pressure: adjust dose based on response. - Assess heart rate: watch for excessive bradycardia. - Evaluate cardiac function: use caution in decompensated heart failure. - Review respiratory status: avoid in uncontrolled asthma or COPD. - Consider renal/hepatic impairment: dose may need adjustment. - Store below 25°C: keep in the original pack, protect from moisture.

Metoprolol Alvogen can interact with other medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Concomitant use with non‑selective beta blockers: additive bradycardia. - Combined with calcium‑channel blockers (verapamil, diltiazem): risk of severe AV block. - Concurrent MAO inhibitors: enhanced hypotensive effect.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive efficacy. - Antidiabetic agents: may mask hypoglycemia symptoms. - SSRIs and other antidepressants: potential for increased bradycardia. - Digoxin: may raise serum digoxin concentrations.